Annual General Meeting

2013

OBJ LimitedLeaders in magnetic enhanced drug delivery technology, products and solutions

For

per

sona

l use

onl

y

DDisclaimerisThis Presentation has been prepared by OBJ Limited (ABN 72 056 482 636) (OBJ or the Company). This Presentation contains summary information aboutOBJ and its activities current as at the date of this Presentation. The information in this Presentation is of general background and does not purport to becomplete or to comprise all the information that a shareholder or potential investor in OBJ may require in order to determine whether to deal in OBJshares. It should be read in conjunction with OBJ’s other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange(ASX), which are available at www.asx.com.au. This document is not a prospectus or a product disclosure statement under the Corporations Act (Cth) 2001(Corporations Act) and has not been lodged with the Australian Securities and Investments Commission (ASIC).Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication offuture performance.This Presentation contains certain “forward‐looking statements”. The words “expect”, “should”, “could”, “may”, “will, “predict”, “plan”, “scenario”,“forecasts”, “anticipates”, “outlook” and other similar expressions are intended to identify forward‐looking statements. Indications of, and guidance on,future earnings and financial position and performance are also forward‐looking statements. Where the Company expresses or implies an expectation orbelief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. Forward‐lookingstatements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice,as are statements about market and industry trends, which are based on interpretations of current market conditions. Such forward‐looking statementsincluding projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication orguarantee of future performance. There can be no assurance that actual outcomes will not differ materially from these forward‐looking statements, andthere are risks associated with the Company and the industry (including those set out below) which may affect the accuracy of the forward‐lookingstatements. The Company does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events orcircumstances after the date of this presentation, or to reflect the occurrence of unanticipated events, except as may be required under applicablesecurities laws.This document may not be released or distributed in the United States. This Presentation does not constitute an offer to sell, or the solicitation of an offerto buy, any securities in the United States. Securities in the Company have not been, and will not be, registered under the U.S. Securities Act of 1933 or thesecurities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States unless the securities are registeredunder the Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration.

To the maximum extent permitted by law, OBJ and its respective advisers and affiliates, directors, officers and employees make no representation orwarranty, express or implied, as to the accuracy, reliability or completeness of information in the Presentation.F

or p

erso

nal u

se o

nly

Developing and partnering the creation of next generation products in

Cosmetics and Skincare, Consumer Healthcare, Oral Health and Pharmaceutical Products

For

per

sona

l use

onl

y

Highlights of 2013 Procter & Gamble

Following completion of a clinical study into the effect of OBJ’s magnetic microarray technology, P&G and OBJ are in negotiation regarding the possible product development of the first application for OBJ’s technology within  P&G’s product range.  

For

per

sona

l use

onl

y

Highlights of 2013 Coty and Philosophy

Philosophy completed a large clinical efficacy study using OBJ’s powered technology during 2013. 

In response to the outcomes, Philosophy and OBJ  are currently negotiating  a Product Development Agreement.

For

per

sona

l use

onl

y

Highlights of 2013 GlaxoSmithKline (Oral Health)

Completion of multiple ex‐vivo studies in the UK under the GSK Collaboration Agreement, the first in‐mouth studies in humans and more recent progress  with additional key  ingredient studies have resulted in a large clinical efficacy study to be undertaken in the UK. 

For

per

sona

l use

onl

y

Highlights of 2013 GlaxoSmithKline (Pharmaceuticals)

Completion of the Phase 1 optimization program under the GSK Collaboration Agreement using OBJ’s Field‐in‐Motion technology has resulted in negotiations to expand into a  larger Phase 2 program. 

For

per

sona

l use

onl

y

OBJ’s Own Products ‐ BodyGuard

2013 has seen major progress in the Company’s Bodyguard programme with the first product currently under clinical trialing under the supervision of Professor Tony Wright. 

Highlights of 2013

For

per

sona

l use

onl

y

Other Highlights

• Appointed Operations Manager to oversee production and manufacturing

• New test models and expertise has extended OBJ’s influence with partners

• Expenditure has been strictly contained.• Capital raising now ensures the Company is well capitalised to meet immediate needs.For

per

sona

l use

onl

y

For

per

sona

l use

onl

y

BODYGUARD  PROJECT  UPDATE  George  Tsadilas  

OBJ F

or p

erso

nal u

se o

nly

DISCLAIMER  This  Presenta,on  has  been  prepared  by  OBJ  Limited  (ABN  72  056  482  636)  (OBJ  or  the  Company).  This  Presenta,on  contains  summary  informa,on   about  OBJ   and   its   ac,vi,es   current   as   at   the  date  of   this   Presenta,on.   The   informa,on   in   this   Presenta,on   is   of   general  background  and  does  not  purport  to  be  complete  or  to  comprise  all  the  informa,on  that  a  shareholder  or  poten,al  investor  in  OBJ  may  require  in  order  to  determine  whether  to  deal  in  OBJ  shares.  It  should  be  read  in  conjunc,on  with  OBJ’s  other  periodic  and  con,nuous  disclosure  announcements  lodged  with  the  Australian  Securi,es  Exchange  (ASX),  which  are  available  at  www.asx.com.au.  This  document  is  not  a  prospectus  or  a  product  disclosure  statement  under  the  Corpora,ons  Act  (Cth)  2001  (Corpora,ons  Act)  and  has  not  been  lodged  with  the  Australian  Securi,es  and  Investments  Commission  (ASIC).  Past  performance   informa,on  given   in  this  Presenta,on   is  given  for  illustra,ve  purposes  only  and  should  not  be  relied  upon  as  (and  is  not)  an  indica,on  of  future  performance.    This  Presenta,on  contains  certain  “forward-­‐looking  statements”.  The  words  “expect”,  “should”,  “could”,  “may”,  “will,  “predict”,  “plan”,  “scenario”,   “forecasts”,   “an,cipates”,   “outlook”   and   other   similar   expressions   are   intended   to   iden,fy   forward-­‐looking   statements.  Indica,ons  of,  and  guidance  on,  future  earnings  and  financial  posi,on  and  performance  are  also  forward-­‐looking  statements.  Where  the  Company  expresses  or  implies  an  expecta,on  or  belief  as  to  future  events  or  results,  such  expecta,on  or  belief  is  expressed  in  good  faith  and  believed  to  have  a  reasonable  basis.  Forward-­‐looking  statements,  opinions  and  es,mates  provided  in  this  Presenta,on  are  based  on  assump,ons  and  con,ngencies  which  are  subject  to  change  without  no,ce,  as  are  statements  about  market  and  industry  trends,  which  are  based  on   interpreta,ons  of   current  market   condi,ons.   Such   forward-­‐looking   statements   including  projec,ons,   guidance  on   future  earnings   and   es,mates   are   provided   as   a   general   guide   only   and   should   not   be   relied   upon   as   an   indica,on   or   guarantee   of   future  performance.  There  can  be  no  assurance  that  actual  outcomes  will  not  differ  materially  from  these  forward-­‐looking  statements,  and  there  are  risks  associated  with  the  Company  and  the   industry   (including  those  set  out  below)  which  may  affect  the  accuracy  of   the  forward-­‐looking  statements.  The  Company  does  not  undertake  any  obliga,on  to  release  publicly  any  revisions  to  any  forward  looking  statement  to  reflect  events  or  circumstances  a_er  the  date  of  this  presenta,on,  or  to  reflect  the  occurrence  of  unan,cipated  events,  except  as  may  be  required  under  applicable  securi,es  laws.    This   document  may   not   be   released  or   distributed   in   the  United   States.   This   Presenta,on  does   not   cons,tute   an   offer   to   sell,   or   the  solicita,on  of  an  offer  to  buy,  any  securi,es   in  the  United  States.  Securi,es   in  the  Company  have  not  been,  and  will  not  be,  registered  under  the  U.S.  Securi,es  Act  of  1933  or  the  securi,es  laws  of  any  state  or  other  jurisdic,on  of  the  United  States,  and  may  not  be  offered  or   sold   in   the   United   States   unless   the   securi,es   are   registered   under   the   Securi,es   Act   or   pursuant   to   an   exemp,on   from,   or   in   a  transac,on  not  subject  to,  registra,on.  To  the  maximum  extent  permibed  by  law,  OBJ    and  its  respec,ve  advisers  and  affiliates,  directors,  officers   and   employees   make   no   representa,on   or   warranty,   express   or   implied,   as   to   the   accuracy,   reliability   or   completeness   of  informa,on  in  the  Presenta,on.  

For

per

sona

l use

onl

y

OVERVIEW  

•  Develop a musculoskeletal patch to address the increasing incidence of of knee pain resulting from degrading cartilage in active people

•  Expedite the commercialisation pathway by developing a market ready product for (a) partnering with a global consumer company or (b) OBJ to launch independently

For

per

sona

l use

onl

y

FORMULATION  

•  Formulation has been optimised to support synovial fluid function •  Developed in conjunction with London School of Pharmacology •  Registered trade name of Lubricen •  Active ingredients are complimented by a permeation enhancer

Chondroitin Sulfate Glycosaminoglycan

Link Protein Hyaluronic Acid backbone

For

per

sona

l use

onl

y

TRANSDERMAL  DELIVERY  

•  Large molecular weight of active ingredients require an intervening force to penetrate the body’s epidermal layers

•  OBJ’s ETP has shown to be significantly more effective at delivering these active ingredients.

For

per

sona

l use

onl

y

MARKET  VALIDATION  

0-­‐2  Not  

interested  

3-­‐4  Fairly  

uninterested  

5    

6-­‐7  Quite  

interested  

8-­‐10  Extremely  interested  

9 7 9 24 51

%  Interest in Product Concept

•  Extensive research conducted: Quantitative (3,000 UK and 1,000 AUS respondents) and Qualitative (8 focus groups in UK)

•  A substantial market of knee pain sufferers exists •  Significant interest in the product concept and for trial purchase •  GP’s and Physios emerged as the key influencers

For

per

sona

l use

onl

y

DESIGN  &  PROTOTYPE  

•  Partnered with Design & Industry to design and engineer prototypes •  Two product directions taken to appeal to a range of lifestyles •  Low cost disposable adhesive patch •  Durable strap with a recurring consumable - formulation pods

encapsulated in a technology module

For

per

sona

l use

onl

y

PRODUCT  TRIAL  

•  Study to test product efficacy and consumer perceptions •  Protocol and study methodology developed by Professor Tony Wright •  20 x active 40-55 year old males with knee pain •  Baseline ALF testing then retest after product intervention

For

per

sona

l use

onl

y

THANK  YOU  

OBJ F

or p

erso

nal u

se o

nly